First, further experimental validation through clinical and functional assays is necessary for the distinct immunophenotypic profiles and functional characteristics identified in this study for the tumor-infiltrating myeloid cells, CD4+ and CD8+ T lymphocyte subsets, and B lymphocyte populations. The gene discussed is CD8A; the disease is neoplasm.